Pigmented pathological type and depth of follicular extension as predictors of treatment failure in 5-aminolevulinic acid photodynamic therapy for actinic keratosis: A retrospective, matched nested case-control study.
{"title":"Pigmented pathological type and depth of follicular extension as predictors of treatment failure in 5-aminolevulinic acid photodynamic therapy for actinic keratosis: A retrospective, matched nested case-control study.","authors":"Qinyuan Zhu, Huyan Chen, Jing Luan, Qiong Huang, Lianjun Chen, Wenyu Wu, Shujun Chen","doi":"10.1016/j.pdpdt.2024.104409","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While 5-Aminolevulinic acid photodynamic therapy (ALA-PDT) is widely used to treat actinic keratosis (AK), treatment resistance and recurrence after ALA-PDT remain significant clinical challenges.</p><p><strong>Methods: </strong>This single-site, retrospective, matched case-control study included 119 patients with histologically confirmed AK to identify clinical and pathological predictors for effectiveness of ALA-PDT. Patients received four consecutive ALA-PDT sessions at intervals of 1 or 2 weeks. Initial complete clearance (ICC) at 3 months and sustained complete clearance (SCC) at 12 months were assessed. Case patients were those with treatment-resistant or recurrent AK, matched with controls based on age, sex, and the treatment date. Baseline characteristics were collected and compared between the case and control groups.</p><p><strong>Results: </strong>ICC at 3 months was achieved in 106 out of 119 patients (89.07%), with 65 out of 82 patients (79.27%) maintaining SCC at 12 months. Pigmented AK emerged as an independent predictor of treatment resistance (OR=44.05, p=0.00). Furthermore, follicular extension to the isthmus or deeper was significantly associated with recurrence within 1 year (OR=17.26, p=0.00).</p><p><strong>Conclusion: </strong>Pigmented AK and AK with follicular extension to the isthmus or deeper may serve as independent predictors of treatment resistance and recurrence, respectively. These findings highlight the importance of these specific features when assessing prognosis and tailoring treatment strategies for individual AK patients.</p>","PeriodicalId":94170,"journal":{"name":"Photodiagnosis and photodynamic therapy","volume":" ","pages":"104409"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photodiagnosis and photodynamic therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pdpdt.2024.104409","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: While 5-Aminolevulinic acid photodynamic therapy (ALA-PDT) is widely used to treat actinic keratosis (AK), treatment resistance and recurrence after ALA-PDT remain significant clinical challenges.
Methods: This single-site, retrospective, matched case-control study included 119 patients with histologically confirmed AK to identify clinical and pathological predictors for effectiveness of ALA-PDT. Patients received four consecutive ALA-PDT sessions at intervals of 1 or 2 weeks. Initial complete clearance (ICC) at 3 months and sustained complete clearance (SCC) at 12 months were assessed. Case patients were those with treatment-resistant or recurrent AK, matched with controls based on age, sex, and the treatment date. Baseline characteristics were collected and compared between the case and control groups.
Results: ICC at 3 months was achieved in 106 out of 119 patients (89.07%), with 65 out of 82 patients (79.27%) maintaining SCC at 12 months. Pigmented AK emerged as an independent predictor of treatment resistance (OR=44.05, p=0.00). Furthermore, follicular extension to the isthmus or deeper was significantly associated with recurrence within 1 year (OR=17.26, p=0.00).
Conclusion: Pigmented AK and AK with follicular extension to the isthmus or deeper may serve as independent predictors of treatment resistance and recurrence, respectively. These findings highlight the importance of these specific features when assessing prognosis and tailoring treatment strategies for individual AK patients.
背景:尽管5-氨基乙酰丙酸光动力疗法(ALA-PDT)被广泛用于治疗光化性角化病(AK),但ALA-PDT治疗后的耐药性和复发仍是重大的临床挑战:这项单一地点、回顾性、匹配病例对照研究纳入了119例经组织学确诊的AK患者,以确定ALA-PDT疗效的临床和病理预测因素。患者连续接受四次 ALA-PDT 治疗,每次间隔 1 或 2 周。评估3个月时的初始完全清除率(ICC)和12个月时的持续完全清除率(SCC)。病例患者为治疗耐药或复发的 AK 患者,与对照组根据年龄、性别和治疗日期进行配对。收集病例组和对照组的基线特征并进行比较:119例患者中有106例(89.07%)在3个月时达到ICC,82例患者中有65例(79.27%)在12个月时保持SCC。色素性 AK 是耐药性的独立预测因素(OR=44.05,P=0.00)。此外,滤泡扩展到峡部或更深层与一年内复发显著相关(OR=17.26,P=0.00):结论:色素性 AK 和毛囊扩展至峡部或更深部位的 AK 可分别作为耐药和复发的独立预测因素。这些发现强调了在评估预后和为个体AK患者量身定制治疗策略时,这些特殊特征的重要性。